Corvus Pharmaceuticals
CRVS
54 hedge funds and large institutions have $180M invested in Corvus Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 8 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
0% more funds holding
Funds holding: 54 → 54 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.99% less ownership
Funds ownership: 83.78% → 82.79% (-0.99%)
35% less capital invested
Capital invested by funds: $280M → $180M (-$99.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.39M |
| 2 |
BlackRock
New York
|
+$3.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$527K |
| 4 |
Renaissance Technologies
New York
|
+$511K |
| 5 |
Millennium Management
New York
|
+$487K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$5.45M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.11M |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$1.19M |
| 5 |
JP Morgan Chase
New York
|
-$906K |
CRVS Hedge Fund Activity: Q4 2017 in Review
54 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2017, worth a combined $180M — down 35% from $280M a quarter earlier.
Fund positioning in CRVS was balanced in Q4 2017: 8 funds opened new positions, 8 closed out, 21 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $5.39M. The largest seller was Jennison Associates, cutting an estimated $5.45M.
- 54 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $180M of Corvus Pharmaceuticals stock for Q4 2017, down 35% quarter-over-quarter.
- 8 funds opened new Corvus Pharmaceuticals positions in Q4 2017 and 8 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2017 was Fidelity Investments, an estimated $5.39M added.
- The largest Corvus Pharmaceuticals seller in Q4 2017 was Jennison Associates, an estimated $5.45M sold.
Based on aggregated 13F filings for Q4 2017.